Cover Image


Point-of-Delivery Drug Reconstitution Systems to 2017: Markets, Strategies and Prospects

出版商 Greystone Research Associates 商品編碼 111920
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
針點注射給藥的藥物的復原·溶解系統:市場·策略·展望 Point-of-Delivery Drug Reconstitution Systems to 2017: Markets, Strategies and Prospects
出版日期: 2013年01月02日 內容資訊: 英文





  • 延長生物製藥的有效期
  • 流通策略
  • 配藥策略
  • 凍結乾燥和利用現場的復原·溶解
  • 醫療部門的經濟學復原·溶解系統


  • 生物製藥的普及
  • 自我施打的趨勢
  • 人口動態的變化
  • 設備的拋棄式用品設計的創新
  • 治療需求的推動因素
  • 競爭環境
  • 風險因素


  • 瓶子配接器
  • 瓶對瓶系統
  • 無針藥物轉移設備
  • 瓶子的直接連接
  • 筆式小管的直接連接
  • 雙室注射器
  • 雙室筆式小管
  • 封閉式藥物轉移
  • 復原·溶解系統的設計因素
  • 穩定性材料選擇的課題
  • 藥物的拋棄式筆式小管
  • 單次 vs 複數施打設備
  • 人機學/人體工學





Product Code: RRSPD212F

Greystone Research Associates is pleased to announce the publication of a new market study. Point-of-Delivery Drug Reconstitution Systems to 2017 is a comprehensive evaluation and analysis of the technology, devices and participants behind the innovative approaches that address the growing need for packaging and delivering lyophilized drugs for injection.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for reconstituting lyophilized drugs at the point of use. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Innovative Devices and the Growth of Reconstituted Drugs

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a distribution strategy referred to as the ‘Cold Chain'. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

Table of Contents

Executive Summary

Market Dynamics

  • Prolonging the Shelf Life of Biological Drugs
  • Distribution Strategies
  • Formulation Strategies
  • Lyophilization and Reconstitution at the Point of Use
  • Healthcare Economics and Reconstitution Systems

What's Driving the Growth in Engineered Reconstitution Systems?

  • Biological Drugs Proliferating
  • The Trend toward Self-Administration
  • Shifting Demographics
  • Innovation in Disposable Device Designs
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors

Drug Reconstitution Systems - Commercial Devices

  • Vial Adapters
  • Vial-to-Vial Systems
  • Needle-less Transfer Devices
  • Direct Connect to Vial
  • Direct Connect to Cartridge
  • Dual Chamber Syringes
  • Dual Chamber Cartridges
  • Closed Drug Transfer
  • Reconstitution System Design Factors
  • Stability and Material Selection Issues
  • Disposable Drug Cartridges
  • Single vs Multi-Dose Devices
  • Human Engineering/Ergonomics

Drug Reconstitution - Therapeutic Sector Analysis

  • Antibiotics/Antivirals
  • Antibodies
  • Autoimmune Diseases
  • Arthritis
  • Crohn's Disease
  • Lupus
  • Multiple Sclerosis
  • Psoriasis
  • Blood Proteins
  • Hepatitis
  • Hemostats
  • Hormone Replacement
  • Human Growth Hormone
  • Oncology
  • Osteoporosis
  • Reproductive Medicine
  • Vaccines
  • Market Sector Drivers
  • Competitive Climate
  • Osteoporosis Therapies

Market Factors

  • Syringe Disposal
  • Regulatory Issues
  • Patient Compliance
  • Healthcare Economics

Drug Reconstitution Systems - Company Profiles

Back to Top